Source link : https://newshealth.biz/health-news/fate-of-myeloma-drugs-comeback-now-rests-in-hands-of-fda-panel/
(MedPage Today) — FDA staff noted that the benefit-risk profile of belantamab mafodotin (Blenrep) in relapsed and refractory multiple myeloma remains murky given its checkered history in a briefing document released ahead of a meeting of the agency… Source link : https://www.medpagetoday.com/hematologyoncology/myeloma/116511 Author : Publish date : 2025-07-15 20:03:00 Copyright for syndicated content belongs to […]
The post Fate of Myeloma Drug’s Comeback Now Rests in Hands of FDA Panel first appeared on News Health.
—-
Author : News Health
Publish date : 2025-07-15 20:03:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8